Teva and Perrigo announced the launch of Temozolomide Capsules, the generic version of Merck’s Temodar.

Temodar is an alkylating agent indicated for the treatment of adult patients with newly diagnosed glioblastoma multiforme concomitantly with radiotherapy and then as maintenance treatment and refractory anaplastic astrocytoma patients who have experienced disease progression on a drug regimen containing nitrosourea and procarbazine.

RELATED: Oncology Resource Center

Temozolomide is not directly active but undergoes rapid nonenzymatic conversion at physiologic pH to the reactive compound 5-(3-methyltriazen-1-yl)-imidazole-4-carboxamide (MTIC). The cytotoxicity of MTIC is thought to be primarily due to alkylation of DNA.

Teva will manufacture, market, and distribute the product in the U.S.

For more information call (866) 634-9120 or visit